These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer. Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991 [No Abstract] [Full Text] [Related]
25. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. Siefker-Radtke AO Expert Rev Anticancer Ther; 2009 Dec; 9(12):1701-3. PubMed ID: 19954279 [No Abstract] [Full Text] [Related]
29. Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract. Furihata M; Kurabayashl A; Matsumoto M; Sonobe H; Ohtsuki Y; Terao N; Kuwahara M; Shuin T J Pathol; 2002 May; 197(1):82-8. PubMed ID: 12081208 [TBL] [Abstract][Full Text] [Related]
30. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. Chung SD; Lai MK; Chueh SC BJU Int; 2008 Aug; 102(4):519. PubMed ID: 18699962 [No Abstract] [Full Text] [Related]
32. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas. Nakagawa T; Kanai Y; Ushijima S; Kitamura T; Kakizoe T; Hirohashi S J Urol; 2005 Jan; 173(1):243-6. PubMed ID: 15592089 [TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954 [TBL] [Abstract][Full Text] [Related]